tranexamic acid and Placental Abruption studies

Research Excerpts

Excerpt	Relevance	Reference
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e."	7.68	Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993)
"Abruptio placentae is known to have a bad prognosis for the fetus."	5.26	Abruptio placentae--treatment with the fibrinolytic inhibitor tranexamic acid. ( Astedt, B; Nilsson, IM; Svanberg, L, 1980)
"In cases of placental abruption complicated with disseminated intravascular coagulation, intrapartum administration of coagulation factors can simultaneously promote effective labor and correct hypofibrinogenemia, enabling minimally invasive vaginal delivery."	3.80	Intrapartum anti-disseminated intravascular coagulation therapy leading to successful vaginal delivery following intrauterine fetal death caused by placental abruption: a case report. ( Baba, K; Era, S; Honda, M; Matsunaga, S; Seki, H; Takai, Y, 2014)
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e."	3.68	Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993)
" The effectiveness of treatment methods and the optimal dosage of misoprostol are research priorities."	2.53	Preventing deaths due to haemorrhage. ( Hofmeyr, GJ; Qureshi, Z, 2016)
"Abruptio placentae is known to have a bad prognosis for the fetus."	1.26	Abruptio placentae--treatment with the fibrinolytic inhibitor tranexamic acid. ( Astedt, B; Nilsson, IM; Svanberg, L, 1980)

Research

Studies (7)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Median Number of Transfused Units of Red Blood Cells (RBC)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (57.14)	18.7374
1990's	1 (14.29)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (28.57)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Honda, M	1
Matsunaga, S	1
Era, S	1
Takai, Y	1
Baba, K	1
Seki, H	1
Hofmeyr, GJ	1
Qureshi, Z	1
Svanberg, L	1
Astedt, B	3
Nilsson, IM	2
Lindoff, C	1
Rybo, G	1
Wardle, EN	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128]	Phase 4	50 participants (Anticipated)	Interventional	2021-08-01	Not yet recruiting
Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116]	Phase 4	100 participants (Actual)	Interventional	2008-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Number of Patients Receiving Blood Transfusions

Intervention	units (Median)
The Placebo Group	2
The Tranexamic Acid Group	2

Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Number of Patients With Clinically or Radiologically Verified Thromboembolic Events Within 5 Weeks Postoperatively

Intervention	participants (Number)
Tranexamic Group	15
Placebo Group	22

Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.

Number of Units of Red Blood Cells (RBC) Transfused

Intervention	Participants (Count of Participants)
Tranexamic Group	2
Placebo Group	5

Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Perioperative Bleeding Volume

Intervention	units (Number)
Tranexamic Group	38
Placebo Group	53

Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Article	Year
Intrapartum anti-disseminated intravascular coagulation therapy leading to successful vaginal delivery following intrauterine fetal death caused by placental abruption: a case report. Journal of medical case reports, 2014, Dec-23, Volume: 8 Topics: Abruptio Placentae; Adult; Antifibrinolytic Agents; Coagulants; Delivery, Obstetric; Disseminated In	2014
Abruptio placentae--treatment with the fibrinolytic inhibitor tranexamic acid. Acta obstetricia et gynecologica Scandinavica, 1980, Volume: 59, Issue:2 Topics: Abruptio Placentae; alpha-Macroglobulins; Antithrombin III; Blood Coagulation Factors; Cesarean Sect	1980
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Recurrent abruptio placentae treated with the fibrinolytic inhibitor tranexamic acid. British medical journal, 1978, Mar-25, Volume: 1, Issue:6115 Topics: Abruptio Placentae; Cyclohexanecarboxylic Acids; Female; Humans; Pregnancy; Recurrence; Tranexamic A	1978
Inhibition of fibrinolysis and abruptio placentae. British medical journal, 1978, May-13, Volume: 1, Issue:6122 Topics: Abruptio Placentae; Cyclohexanecarboxylic Acids; Female; Fibrinolysis; Humans; Pregnancy; Tranexamic	1978
Inhibition of fibrinolysis and abruptio placentae. British medical journal, 1978, Sep-30, Volume: 2, Issue:6142 Topics: Abruptio Placentae; Cyclohexanecarboxylic Acids; Female; Fetal Death; Humans; Pregnancy; Tranexamic	1978

tranexamic acid and Placental Abruption